Drugs and therapies – Page 20
-
ArticleThe first multi-chamber heart organoids developed
The first multi-chamber cardioids derived from hiPSCs have enabled scientists to investigate heart development and defects.
-
ArticleNew understanding of the TMEJ pathway in cancer
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
-
ArticleThe first major set of genetic associations found in long COVID
PrecisionLife’s Dr Sayoni Das, a computational biologist who leads the research and development of bioinformatics pipelines that generate biological insights from PrecisionLife’s core technology and support drug discovery programmes, details a new study. Using combinatorial analysis, genetic variants associated with long COVID have been identified and, furthermore, it has been ...
-
Article
Phages could help to tackle antimicrobial resistance
Researchers have found what triggers bacteria to start the CBASS immune response to counter infections by phages.
-
ReportBeyond the lab: RNA
Download this exclusive content focusing on new RNA editing technology, the challenges and opportunities presented and the potential of RNA-based therapeutics.
-
ReportBeyond the lab: cancer research
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
-
ArticleNew technology optimises mesenchymal stem cell extraction
A continuous sorting technique of stem cells on a DLD microfluidic platform may greatly advance cell therapy.
-
ArticleWomen in Stem with Andrea Pfeifer
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership, ...
-
ArticleExploring liver disease therapies
Ochre Bio is at the forefront of therapeutic innovation, focusing primarily on liver diseases. Their core mission revolves around the development of RNA therapies, primarily in the preclinical stage, using a 'human-first' approach. They employ real human tissue, such as 'liver slices' and whole human livers, in their preclinical pipeline ...
-
ArticleThe role of STRIs in cancer
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance ...
-
ArticleThe effectiveness of nanoparticles in chemotherapy
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
-
ArticleCombining autotaxin and TGF-β inhibitors in cancer
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and ...
-
ArticleCAR-NK cells: promising for cancer therapy
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
-
Article
Natural killer cells: Looking good for cancer therapy
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field?
-
ArticleAntimicrobial resistance with Recce Pharmaceuticals
In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of ...
-
ArticleBreaking down barriers across the DMTA cycle
In this article, David Bardsley, Commercial Director, and Nick Foster, Vice President of Discovery CRO at Cresset, explore the challenges that occur when approaching drug discovery in silos and how harnessing advances in technology can help to overcome them.
-
ArticleBreaking new ground in endometriosis treatment
Endometriosis is a debilitating condition that affects millions of women worldwide, causing chronic pain, infertility, and a host of other distressing symptoms. Current treatments offer limited relief, but they do not address the cause of the disease. Professor Hugo Vankelecom, at the helm of the CurE-me project, is on a ...
-
ArticleNavigating the challenges of cell therapies
Cell therapies hold great potential for treating complex diseases, yet they face significant limitations and challenges. Current cell therapies have difficulty distinguishing between healthy and cancerous cells, often resulting in adverse effects. Vittoria's innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of ...
-
ArticleThe power of combinations in blood cancers
Haematology research is a cradle of innovation, with many firsts in therapeutic approaches utilising the latest technology for the treatment of blood cancers. Anas Younes, Senior Vice President, Head of Haematology Oncology Research and Development at AstraZeneca, envisions a future where potential cures are within reach for more blood cancers ...
-
ArticleCancer drug discovery: protein-ligand interactions
Dr Rob van Montfort, a leading researcher at the Centre for Cancer Drug Discovery (CCDD) within The Institute of Cancer Research, London, is at the forefront of cancer drug discovery. Focusing on protein-ligand interactions, his work utilises structural biology and biochemical methods to help the discovery of novel small-molecule drugs ...